Alfonso Zambon

Laboratorio dei Biomateriali, Dipartimento di Scienze Mediche Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Via G. Campi 213/A, 41125 Modena, Italy.

View Article and Find Full Text PDF

February 2019

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Cancer Cell 2017 03;31(3):466

View Article and Find Full Text PDF

March 2017

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Cancer Cell 2015 Jan 11;27(1):85-96. Epub 2014 Dec 11.

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK. Electronic address:

View Article and Find Full Text PDF

January 2015

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Authors:

Berta Sanchez-Laorden Amaya Viros Maria Romina Girotti Malin Pedersen Grazia Saturno Alfonso Zambon Dan Niculescu-Duvaz Samra Turajlic Andrew Hayes Martin Gore James Larkin Paul Lorigan Martin Cook Caroline Springer Richard Marais

Sci Signal 2014 Mar 25;7(318):ra30. Epub 2014 Mar 25.

1Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.

View Article and Find Full Text PDF

March 2014

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

Authors:

Dan Niculescu-Duvaz Ion Niculescu-Duvaz Bart M J M Suijkerbuijk Delphine Ménard Alfonso Zambon Lawrence Davies Jean-Francois Pons Steven Whittaker Richard Marais Caroline J Springer

Bioorg Med Chem 2013 Mar 3;21(5):1284-304. Epub 2013 Jan 3.

The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF

March 2013

BRAF as a therapeutic target: a patent review (2006 - 2012).

Authors:

Alfonso Zambon Dan Niculescu-Duvaz Ion Niculescu-Duvaz Richard Marais Caroline J Springer

Expert Opin Ther Pat 2013 Feb 7;23(2):155-64. Epub 2013 Jan 7.

The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.

View Article and Find Full Text PDF

February 2013

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Authors:

Maria R Girotti Malin Pedersen Berta Sanchez-Laorden Amaya Viros Samra Turajlic Dan Niculescu-Duvaz Alfonso Zambon John Sinclair Andrew Hayes Martin Gore Paul Lorigan Caroline Springer James Larkin Claus Jorgensen Richard Marais

Cancer Discov 2013 Feb 14;3(2):158-67. Epub 2012 Dec 14.

Signal Transduction Team, The Institute of Cancer Research, Royal Marsden Hospital, London, UK.

View Article and Find Full Text PDF

February 2013

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

Authors:

Amaya Viros Robert Hayward Matthew Martin Sharona Yashar Clarissa C Yu Berta Sanchez-Laorden Alfonso Zambon Dan Niculescu-Duvaz Caroline Springer Roger S Lo Richard Marais

J Invest Dermatol 2013 Jan 16;133(1):274-6. Epub 2012 Aug 16.

Seccio Dermatologia, Departament de Medicina, Hospital Universitari Vall d’Hebron, Universitat Autonomade Barcelona, Spain.

View Article and Find Full Text PDF

January 2013

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

N Engl J Med 2012 Jan;366(3):207-15

Hoffmann-La Roche, Nutley, NJ, USA.

View Article and Find Full Text PDF

January 2012

Small molecule inhibitors of BRAF in clinical trials.

Authors:

Alfonso Zambon Ion Niculescu-Duvaz Dan Niculescu-Duvaz Richard Marais Caroline J Springer

Bioorg Med Chem Lett 2012 Jan 3;22(2):789-92. Epub 2011 Dec 3.

The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF

January 2012

A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.

Authors:

Steven Whittaker Delphine Ménard Ruth Kirk Lesley Ogilvie Douglas Hedley Alfonso Zambon Filipa Lopes Natasha Preece Helen Manne Sareena Rana Maryou Lambros Jorge S Reis-Filho Richard Marais Caroline J Springer

Cancer Res 2010 Oct 31;70(20):8036-44. Epub 2010 Aug 31.

Signal Transduction Team, Section of Cell and Molecular Biology, Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article and Find Full Text PDF

October 2010

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.

Bioorg Med Chem 2010 Sep 15;18(18):6934-52. Epub 2010 Jun 15.

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF

September 2010

Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.

Authors:

Alfonso Zambon Delphine Ménard Bart M J M Suijkerbuijk Ion Niculescu-Duvaz Steven Whittaker Dan Niculescu-Duvaz Arnaud Nourry Lawrence Davies Helen A Manne Filipa Lopes Natasha Preece Douglas Hedley Lesley M Ogilvie Ruth Kirk Richard Marais Caroline J Springer

J Med Chem 2010 Aug;53(15):5639-55

The Institute of Cancer Research, Cancer Research UK Centre for Cancer Therapeutics, Sutton, Surrey, UK.

View Article and Find Full Text PDF

August 2010

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

Authors:

Steven Whittaker Ruth Kirk Robert Hayward Alfonso Zambon Amaya Viros Neus Cantarino Annette Affolter Arnaud Nourry Dan Niculescu-Duvaz Caroline Springer Richard Marais

Sci Transl Med 2010 Jun;2(35):35ra41

Institute of Cancer Research, London, UK.

View Article and Find Full Text PDF

June 2010

Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.

J Med Chem 2010 Apr;53(7):2741-56

The Institute of Cancer Research, Cancer Research UK Centre for Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF

April 2010

BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.

Authors:

Arnaud Nourry Alfonso Zambon Lawrence Davies Ion Niculescu-Duvaz Harmen P Dijkstra Delphine Ménard Catherine Gaulon Dan Niculescu-Duvaz Bart M J M Suijkerbuijk Frank Friedlos Helen A Manne Ruth Kirk Steven Whittaker Richard Marais Caroline J Springer

J Med Chem 2010 Mar;53(5):1964-78

Cancer Research UK Centre of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF

March 2010

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

Authors:

Luca Mologni Roberta Rostagno Stefania Brussolo Phillip P Knowles Svend Kjaer Judith Murray-Rust Enrico Rosso Alfonso Zambon Leonardo Scapozza Neil Q McDonald Vittorio Lucchini Carlo Gambacorti-Passerini

Bioorg Med Chem 2010 Feb 11;18(4):1482-96. Epub 2010 Jan 11.

Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.

View Article and Find Full Text PDF

February 2010

Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.

Authors:

Delphine Ménard Ion Niculescu-Duvaz Harmen P Dijkstra Dan Niculescu-Duvaz Bart M J M Suijkerbuijk Alfonso Zambon Arnaud Nourry Esteban Roman Lawrence Davies Helen A Manne Frank Friedlos Ruth Kirk Steven Whittaker Adrian Gill Richard D Taylor Richard Marais Caroline J Springer

J Med Chem 2009 Jul;52(13):3881-91

The Institute of Cancer Research, UK Centre for Cancer Therapeutics, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF

July 2009

Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).

J Med Chem 2009 Apr;52(8):2255-64

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

View Article and Find Full Text PDF

April 2009

Characterization of compound 584, an Abl kinase inhibitor with lasting effects.

Authors:

Miriam Puttini Sara Redaelli Loris Moretti Stefania Brussolo Rosalind H Gunby Luca Mologni Edoardo Marchesi Loredana Cleris Arianna Donella-Deana Peter Drueckes Elisa Sala Vittorio Lucchini Michael Kubbutat Franca Formelli Alfonso Zambon Leonardo Scapozza Carlo Gambacorti-Passerini

Haematologica 2008 May 26;93(5):653-61. Epub 2008 Mar 26.

School of Pharmaceutical Sciences, University of Geneva, Quai Ernest-Ansermet 30, 1211 Genève 4, Switzerland.

View Article and Find Full Text PDF

May 2008

Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives.

Authors:

Sabine Kuettel Alfonso Zambon Marcel Kaiser Reto Brun Leonardo Scapozza Remo Perozzo

J Med Chem 2007 Nov 20;50(23):5833-9. Epub 2007 Oct 20.

Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, Quai Ernest-Ansermet 30, CH-1211 Geneva 4, Switzerland.

View Article and Find Full Text PDF

November 2007

Chiral polycyclic ketones via desymmetrization of dihaloolefins.

Authors:

Giuseppe Borsato Anthony Linden Ottorino De Lucchi Vittorio Lucchini David Wolstenholme Alfonso Zambon

J Org Chem 2007 May 3;72(11):4272-5. Epub 2007 May 3.

Dipartimento di Scienze Ambientali and Dipartimento di Chimica, Università Ca' Foscari di Venezia, Dorsoduro 2137, I-30123 Venezia, Italy.

View Article and Find Full Text PDF

May 2007

Development and exploitation of CK2 inhibitors.

Authors:

Stefania Sarno Maria Ruzzene Pietrogiulio Frascella Mario A Pagano Flavio Meggio Alfonso Zambon Marco Mazzorana Giovanni Di Maira Vittorio Lucchini Lorenzo A Pinna

Mol Cell Biochem 2005 Jun;274(1-2):69-76

Dipartimento di Chimica Biologica, Universita' di Padova, Padova, Italy.

View Article and Find Full Text PDF

June 2005

"Hexacarboxytrindanes": benzene rings with homotopic faces as scaffolds for the construction of D3 chiral architectures.

Authors:

Giuseppe Borsato Marco Crisma Ottorino De Lucchi Vittorio Lucchini Alfonso Zambon

Angew Chem Int Ed Engl 2005 Dec;44(45):7435-9

Dipartimento di Scienze Ambientali, Università Ca' Foscari di Venezia, Dorsoduro 2137, 30123 Venice, Italy.

View Article and Find Full Text PDF

December 2005

Internal motions in a fulleropyrrolidine tertiary amide with axial chirality.

Authors:

Giuseppe Borsato Federico Della Negra Francesco Gasparrini Domenico Misiti Vittorio Lucchini Giorgia Possamai Claudio Villani Alfonso Zambon

J Org Chem 2004 Aug;69(17):5785-8

Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Università di Roma "La Sapienza", P. le A. Moro 5, 00185 Roma, Italy.

View Article and Find Full Text PDF

August 2004

Efficient cyclotrimerization of bicyclic vic-bromostannylalkenes promoted by copper(I) thiophen-2-carboxylate.

Authors:

Giuseppe Borsato Ottorino De Lucchi Fabrizio Fabris Luca Groppo Vittorio Lucchini Alfonso Zambon

J Org Chem 2002 Nov;67(22):7894-7

Dipartimento di Scienze Ambientali and Dipartimento di Chimica, Università Ca' Foscari di Venezia, Dorsoduro 2137, Italy.

View Article and Find Full Text PDF

November 2002

Substituted aniline interaction with submitochondrial particles and quantitative structure-activity relationships.

Authors:

Emanuele Argese Cinzia Bettiol Matteo Fasolo Alfonso Zambon Francesca Agnoli

Biochim Biophys Acta 2002 Feb;1558(2):151-60

Department of Environmental Sciences, Università Ca' Foscari di Venezia, Calle larga S. Marta 2137, 30123 Venice, Italy.

View Article and Find Full Text PDF

February 2002

Publications by authors named "Alfonso Zambon"

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors: